Calcilytix Therapeutics
www.calcilytix.comCalcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.
Read moreCalcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.
Read moreCountry
State
California
City (Headquarters)
San Francisco
Industry
Employees
11-50
Social
Employees statistics
View all employeesPotential Decision Makers
Senior Vice President , Corporate Development
Email ****** @****.comPhone (***) ****-****Chief Medical Officer
Email ****** @****.comPhone (***) ****-****Director
Email ****** @****.comPhone (***) ****-****
Technologies
(3)